Benzinga

Benzinga

Benzinga

jueves, agosto 27

Revolution Medicines Inc

RVMDNASDAQ
Trade with Public
Trade with Public
$220.15
4.712.18%
Últ. Act.: Aug 27, 1:12 PM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Revolution Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revolution Medicines (RVMD).

Price Target Range — 8 Quarters

Analyst Consensus — 21 Analysts

1S.Buy
19Buy
1Hold
Consensus RatingBuy# Analysts21Avg. Consensus PT$164Upside to Avg. PT-25.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026OppenheimerJay OlsonPT RaiseOutperform$230→$260
Aug 27, 2026RBC CapitalLeonid TimashevPT RaiseOutperform$203→$251
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $203 to $251.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $225

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $201 to $225.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $231 to $239.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $320.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $280

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $195 to $280.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved